Determining decision limits for new biomarkers: Clinical and statistical considerations

Clinical Chemistry

Volumn 57, Issue 1, 2011, Pages 1-3

  Morrow, David A ^a   Cook, Nancy R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MYELOPEROXIDASE;

CLINICAL PRACTICE; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; OPTIMISM; PRACTICE GUIDELINE; REVIEW; STATISTICS; VALIDATION STUDY;

BIOLOGICAL MARKERS; CORONARY STENOSIS; DECISION SUPPORT TECHNIQUES; HUMANS; PEROXIDASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES; ROC CURVE; VALIDATION STUDIES AS TOPIC;

EID: 78650995701     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.155879     Document Type: Review

References (14)

1. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949-52.
2. Tang WHW, Wu Y, Nicholls SJ, Hazen SL. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 2010;57:33-9.
3. Morrow DA, Antman EM. Evaluation of high-sensitivity assays for cardiac troponin. Clin Chem 2009;55:5-8.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007;53:552-74.
6. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2005;27:330-7.
7. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004;93:1238-42.
8. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-5.
9. Vickers AJ, Elkin EB. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 2006;26:565-74.
10. Harrell FE Jr. Regression modeling strategies. New York: Springer; 2001.
11. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35.
12. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new biomarker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
13. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: The role of reclassification measures. Ann Intern Med 2009;150:795-802.
14. Pepe MS, Feng Z, Gu JW. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/ sim.2929). Stat Med 2008;27:173-81.